Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

The sector-specific tariffs are putting pressure on businesses and foreign nations as they try to navigate Trump’s constantly ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Australia is “urgently seeking more detail” on U.S. President Donald Trump’s threat to raise tariffs up to 200% on ...

President Donald Trump’s threat to impose 30% tariffs on the European Union starting Aug. 1 disrupted negotiations and risks ...

Irish-made medicines heading to the US face steep new duties, raising alarm among patients, producers and investors on both ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

Australia is evaluating the impact of potential US tariffs of 200% on pharmaceutical imports, Treasurer Jim Chalmers said, while reiterating that his nation’s subsidies for certain drugs are not up ...

Some GOP lawmakers and pro-trade lobbyists are quietly seeking to rein in the most extreme elements of the Trump ...

The news comes as the administration is pushing for pharmaceutical manufacturers reshore drug production in the United States.

President Donald Trump announced plans for hefty tariffs on imported pharmaceuticals and semiconductors, citing national ...